Search
Retatrutide Treatment Options in Los Angeles, CA
A collection of 2 research studies where Retatrutide is the interventional treatment. These studies are located in the Los Angeles, CA. Retatrutide is used for conditions such as Obesity, Overweight and Type 2 Diabetes.
1 - 2 of 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Active Not Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Valley Clinical Trials, Inc., Covina, California +6 locations
Conditions: Obesity, Cardiovascular Diseases
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Active Not Recruiting
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Core Healthcare Group, Cerritos, California +3 locations
Conditions: Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
1 - 2 of 2